Search Page

1

Cite

Share

Current and evolving approaches to individualizing estrogen receptor-based therapy for menopausal women.

Santen RJ, Kagan R, Altomare CJ, Komm B, Mirkin S, Taylor HS. Santen RJ, et al. Among authors: altomare cj. J Clin Endocrinol Metab. 2014 Mar;99(3):733-47. doi: 10.1210/jc.2013-3680. Epub 2014 Jan 1. J Clin Endocrinol Metab. 2014. PMID: 24423357 Review.

Cite

Share

2

Cite

Share

No increase in incidence or risk of recurrence of breast cancer in ospemifene-treated patients with vulvovaginal atrophy (VVA).

Cai B, Simon J, Villa P, Biglia N, Panay N, Djumaeva S, Particco M, Kanakamedala H, Altomare C. Cai B, et al. Among authors: altomare c. Maturitas. 2020 Dec;142:38-44. doi: 10.1016/j.maturitas.2020.06.021. Epub 2020 Jul 10. Maturitas. 2020. PMID: 33158486 Free article.

Cite

Share

3

Cite

Share

Effects of ospemifene on genitourinary health assessed by prospective vulvar-vestibular photography and vaginal/vulvar health indices.

Goldstein I, Simon JA, Kaunitz AM, Altomare C, Yoshida Y, Zhu J, Schaffer S, Soulban G. Goldstein I, et al. Among authors: altomare c. Menopause. 2019 Sep;26(9):994-1001. doi: 10.1097/GME.0000000000001350. Menopause. 2019. PMID: 31453961 Free PMC article. Clinical Trial.

Cite

Share

4

Cite

Share

Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.

Simon JA, Altomare C, Cort S, Jiang W, Pinkerton JV. Simon JA, et al. Among authors: altomare c. J Womens Health (Larchmt). 2018 Jan;27(1):14-23. doi: 10.1089/jwh.2017.6385. Epub 2017 Oct 24. J Womens Health (Larchmt). 2018. PMID: 29064335 Free PMC article. Clinical Trial.

Cite

Share

5

Cite

Share

Knowledge of clinical trials regarding hormone therapy and likelihood of prescribing hormone therapy.

Taylor HS, Kagan R, Altomare CJ, Cort S, Bushmakin AG, Abraham L. Taylor HS, et al. Among authors: altomare cj. Menopause. 2017 Jan;24(1):27-34. doi: 10.1097/GME.0000000000000711. Menopause. 2017. PMID: 27575548

Cite

Share

6

Cite

Share

Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial.

Archer DF, Goldstein SR, Simon JA, Waldbaum AS, Sussman SA, Altomare C, Zhu J, Yoshida Y, Schaffer S, Soulban G. Archer DF, et al. Among authors: altomare c. Menopause. 2019 Jan 28;26(6):611-621. doi: 10.1097/GME.0000000000001292. Menopause. 2019. PMID: 30694917 Free PMC article. Clinical Trial.

Cite

Share

7

Cite

Share

Ospemifene should be used as a single agent without progestin in postmenopausal women with an intact uterus.

Altomare C. Altomare C. Menopause. 2015 Aug;22(8):916. doi: 10.1097/GME.0000000000000512. Menopause. 2015. PMID: 26154275 No abstract available.

Cite

Share

8

Cite

Share

Ospemifene's effect on vasomotor symptoms: a post hoc analysis of phase 2 and 3 clinical data.

Constantine GD, Archer DF, Pollycove R, Jiang W, Altomare C, Pinkerton JV. Constantine GD, et al. Among authors: altomare c. Menopause. 2016 Sep;23(9):957-64. doi: 10.1097/GME.0000000000000656. Menopause. 2016. PMID: 27404027 Clinical Trial.

Cite

Share

9

Cite

Share

Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally.

Bachmann G, Bouchard C, Hoppe D, Ranganath R, Altomare C, Vieweg A, Graepel J, Helzner E. Bachmann G, et al. Among authors: altomare c. Menopause. 2009 Jul-Aug;16(4):719-27. doi: 10.1097/gme.0b013e3181a48c4e. Menopause. 2009. PMID: 19436223 Clinical Trial.

Cite

Share

10

Cite

Share

The impact of multimorbidity on quality of life among midlife women: findings from a U.S. nationally representative survey.

Lang K, Alexander IM, Simon J, Sussman M, Lin I, Menzin J, Friedman M, Dutwin D, Bushmakin AG, Thrift-Perry M, Altomare C, Hsu MA. Lang K, et al. Among authors: altomare c. J Womens Health (Larchmt). 2015 May;24(5):374-83. doi: 10.1089/jwh.2014.4907. J Womens Health (Larchmt). 2015. PMID: 25973799 Free PMC article.

Cite

Share